- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 2 of 11 | 1 | Cision News | ||
| 14.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives SEK 12 million order from global pharmaceutical company - delivery scheduled for 2026 | 3 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the second exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
| 27.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives New Orders for Custom GoBio Columns for the U.S. Gene Therapy Market | 2 | Cision News | ||
| 26.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for WorkBeads Worth 2.65 Million SEK | 2 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes year-end report Q4 2024 | 1 | Cision News | ||
| 14.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies Doubles Production Capacity to Meet Growing Demand | 5 | Cision News | ||
| 10.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a third follow-up order for WorkBeads affimAb worth SEK 4.0 million | 1 | Cision News | ||
| 31.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Follow-Up Order for WorkBeads affimAb Worth 4.6 MSEK | 1 | Cision News | ||
| 14.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Confirms a New Order for WorkBeads affimAb for Use in Antibody Production for 11.2 MSEK | 1 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: The first day to exercise Bio-Works Technologies AB's warrants of series TO 2 is today | 1 | Cision News | ||
| 12.11.24 | BIO-WORKS TECHNOLOGIES AB: Letter of Intent for order of WorkBreads affimAb increased to 11,9 Mkr | 1 | Cision News | ||
| 04.11.24 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a Letter of Intent (LOI) - the anticipated order value is €652,000. | 5 | Cision News | ||
| 07.08.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.08.2024 | 961 | Xetra Newsboard | Das Instrument LY10 AU000000LLO8 LION ONE METALS CDIS EQUITY wird cum Kapitalmassnahme gehandelt am 07.08.2024 und ex Kapitalmassnahme am 08.08.2024 The instrument LY10 AU000000LLO8 LION ONE METALS... ► Artikel lesen | |
| 02.07.24 | Nasdaq Stockholm AB: Delisting of Bio-Works Technologies AB from Nasdaq First North Growth Market | 447 | GlobeNewswire | Bio-Works Technologies AB has applied for its shares to be delisted from Nasdaq
First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the
shares in Bio-Works... ► Artikel lesen | |
| 27.06.24 | Nasdaq Stockholm AB: Bio-Works Technologies AB receives observation status | 290 | GlobeNewswire | On June 26, 2024, Bio-Works Technologies AB (the "Company") issued a press
release where the Company announced its intention to change listing from Nasdaq
First North Growth Market to Spotlight Stock... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,020 | -1,57 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,480 | -36,02 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,860 | -2,10 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 50,000 | +0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | ||
| TEMPUS AI | 52,90 | -1,13 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,740 | -0,42 % | Hohes Potenzial: Merck KGaA vor Milliarden-Deal: US-Krebsspezialist SpringWorks im Visier | © Foto: Arne Dedert/dpaDer deutsche Pharmakonzern Merck plant den Kauf eines vielversprechenden US-Wettbewerbers. Die Gelegenheit ist günstig.Der Darmstädter Pharma- und Technologiekonzern Merck KGaA... ► Artikel lesen | |
| EVOTEC | 7,382 | +0,52 % | Das ist die Nach-Oster-Chance! Evotec, Bayer, BioNTech, Defence Therapeutics und im Fokus | Donald Trump brüskiert seine internationalen Partner, beleidigt namhafte Amerikaner und entzieht Harvard langjährig zugesagte Fördermittel. Wer hätte das gedacht? Die neue US-Regentschaft entpuppt sich... ► Artikel lesen | |
| BIONTECH | 102,10 | -0,10 % | BioNTech Aktie: Leichte Erholung im Fokus | BioNTech zeigt technische Erholungssignale trotz schwieriger Bewertung. Analysten halten an Kaufempfehlungen fest - wohin steuert die Aktie? Die BioNTech-Aktie zeigt nach turbulenten Wochen erste Anzeichen... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,060 | -0,45 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy | - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 29,610 | +0,61 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
| VERVE THERAPEUTICS | 5,760 | -0,35 % | Why Verve Therapeutics Zoomed 40% Higher This Week | ||
| RECURSION PHARMACEUTICALS | 5,740 | -0,17 % | Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? | ||
| VIR BIOTECHNOLOGY | 6,120 | -2,70 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| CG ONCOLOGY | 22,400 | +4,04 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,200 | +0,31 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,095 Euro und damit +6,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.
